Fortrea sees obesity drug development shifting toward long-term health outcomes in 2027

• Obesity drug development is expected to prioritize sustained weight loss and long-term health outcomes in 2027.
• Sponsors may face growing expectations to demonstrate durable benefits, with trials increasingly assessing body composition and physical function.
• Pipeline diversification beyond traditional incretins could create opportunities for personalized treatments in an increasingly competitive market.
• Oral therapies could expand access and improve convenience, potentially addressing barriers to long-term treatment adherence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortrea Holdings Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.